Areplivir

Active substance : Favipiravir
Name in Cyrillic : АРЕПЛИВИР
Favipiravir inhibits SARS-CoV-2 Virus Causing COVID-19. Areplivir is manufactured in Russia by PROMOMED.

Method of administration and dosage

Favipiravir tablets should be taken 30 minutes before meals.
For the treatment of COVID-19 the following dosing regimen is recommended:

For patients weighing < 75 kg :

the full course of administration is 70 tablets.
1st day of therapy : 1600 mg (8 tablets) 2 times
from the 2nd to the 10th day of therapy : 600 mg (3 tablets) 2 times a day

For patients weighing ≥75 kg :

the full course of administration is 90 tablets.
1st day of therapy : 1800 mg (9 tablets) 2 times
from the 2nd to the 10th day of therapy : 800 mg (4 tablets) 2 times a day

Favipiravir should be taken on the basis of the clinical picture and / or after laboratory confirmation of the diagnosis and in the presence of characteristic clinical symptoms.
The total duration of the course of treatment is 10 days or until confirmation of the elimination of the virus, if it occurs earlier (two consecutive negative PCR test results obtained with an interval of at least 24 hours).

Storage conditions : temperature not exceeding 25 °C., keep out of the reach of children.
Shelf life - 2 years.